Research Article
The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma
Table 2
The relationship between RAS mRNA expression and clinical characteristics of patients with cutaneous melanoma (TCGA, Provisional).
| | Characteristics | Cases number | KRAS mRNA expression | NRAS mRNA expression | HRAS mRNA expression | | Low (%) | High (%) | value | Low (%) | High (%) | value | Low (%) | High (%) | value |
| | Age | | | | | | | | | | | | ≤58 | 227 | 124 (54.6) | 103 (45.4) | 0.048 | 124 (54.6) | 103 (45.4) | 0.048 | 121 (53.3) | 106 (46.7) | 0.158 | | >58 | 225 | 102 (45.3) | 123 (54.7) | 102 (45.3) | 123 (54.7) | 105 (46.7) | 120 (53.3) | | Gender | | | | | | | | | | | | Male | 280 | 145 (51.8) | 135 (48.2) | 0.333 | 134 (47.9) | 146 (52.1) | 0.245 | 134 (47.9) | 146 (52.1) | 0.245 | | Female | 172 | 81 (47.1) | 91 (52.9) | 92 (53.5) | 80 (46.5) | 92 (53.5) | 80 (46.5) | | AJCC stage | | | | | | | | | | | | Stages I + II | 214 | 108 (50.5) | 106 (49.5) | 0.759 | 104(48.6) | 110 (51.4) | 0.862 | 100 (46.7) | 114 (53.3) | 0.366 | | Stages III + IV | 188 | 92 (48.9) | 96 (51.1) | 93 (49.5) | 95 (50.5) | 96 (51.1) | 92 (48.9) | | Tumor thickness (mm) | | | | | | | | | | | | ≤2.00 | 134 | 60 (44.8) | 74 (55.2) | 0.061 | 57 (42.5) | 77 (57.5) | 0.078 | 80 (59.7) | 54 (40.3) | 0.002 | | >2.00 | 214 | 119 (55.6) | 95 (44.4) | 113 (52.8) | 101 (47.2) | 91 (42.5) | 123 (57.5) | | Ulceration | | | | | | | | | | | | Absent | 142 | 72 (50.7) | 70 (49.3) | 0.801 | 62 (43.7) | 80 (56.3) | 0.139 | 73 (51.4) | 69 (48.6) | 0.248 | | Present | 163 | 85 (52.1) | 78 (47.9) | 85 (52.1) | 78 (47.9) | 73 (44.8) | 90 (55.2) |
|
|
